Prediction of therapeutic response before and during i.v. cyclophosphamide pulse therapy for interstitial lung disease in systemic sclerosis: A longitudinal observational study. Issue 12 (5th October 2018)

• Record Type: Journal Article
• Authors: Sumida, Hayakazu; Asano, Yoshihide; Tamaki, Zenshiro; Aozasa, Naohiko; Taniguchi, Takashi; Toyama, Tetsuo; Takahashi, Takehiro; Ichimura, Yohei; Noda, Shinji; Akamata, Kaname; Saigusa, Ryosuke; Miyazaki, Miki; Kuwano, Yoshihiro; Yanaba, Koichi; Yoshizaki, Ayumi; Sato, Shinichi
• Is Part Of: Journal of dermatology. Volume 45:Issue 12(2018)
• Page Start: 1425
• Page End: 1433
• Publication Date: 2018-10-05
• Subjects: cyclophosphamide -- interstitial lung disease -- Krebs von den Lungen‐6 -- surfactant protein D -- systemic sclerosis; Dermatology -- Periodicals; Dermatology -- Japan -- Periodicals; Skin -- Diseases -- Periodicals; 616.5005
• DOI: 10.1111/1346-8138.14669
• Languages: English
• ISSNs: 0385-2407

Abstract

Abstract: There have been no established parameters to predict responsiveness to i.v. cyclophosphamide (IVCY) pulse therapy in combination with corticosteroids in patients with interstitial lung disease (ILD) related to systemic sclerosis (SSc). This retrospective study was conducted to determine predictive factors for efficacy of IVCY at the time of before and during the treatment. Thirty‐two Japanese SSc patients, ever treated for ILD with IVCY in combination with prednisolone, were analyzed retrospectively. We performed detailed time‐course analyses of parameters derived from blood samples and pulmonary function tests. With the exclusion of eight unclassified patients, 24 patients were classified into 14 good responders (GR) or 10 poor responders (PR) on the basis of changes in percent predicted diffusing capacity for carbon monoxide (DLco). Pretreatment percent predicted DLco was significantly reduced in PR compared with GR. In addition, serum parameters such as Krebs von den Lungen‐6 (KL‐6), surfactant protein D (SP‐D) and C‐reactive protein were significantly higher in PR than in GR. Furthermore, our time‐course analyses revealed a transient increase in serum KL‐6 levels with a peak at 3 months after the first infusion of cyclophosphamide, which showed no relation to therapeutic efficacy. Moreover, continuously high serum KL‐6 levels (>2000 U/mL) and rapid decrease in SP‐D levels (<200 ng/mL) during IVCY were remarkably characteristic of PR and GR, respectively. ILD severity/activity before treatment and variability of serum KL‐6 and SP‐D levels during treatment may be useful to predict therapeutic effects of IVCY on SSc‐ILD.